DBV’s financing for peanut allergy patch; Eisai divests proton pump inhibitor in Chinanews2025-03-28T14:01:27+00:00March 28th, 2025|Endpoints News|
Nkarta to lay off 34% of staff; Savara’s debt financing dealnews2025-03-27T14:26:21+00:00March 27th, 2025|Endpoints News|
Humacyte to raise $50M; Acrivon to focus on prexasertib in endometrial cancernews2025-03-26T14:10:15+00:00March 26th, 2025|Endpoints News|
Cassava ends work on Alzheimer’s drug; Alumis gets $40M upfront from Kakennews2025-03-25T14:19:35+00:00March 25th, 2025|Endpoints News|
Surrozen raises $175M, to focus on ophthalmology; CBC Group has a new $1B fundnews2025-03-24T14:57:42+00:00March 24th, 2025|Endpoints News|
Genfit’s up to €185M royalty deal; J&J’s Tremfya gets a Crohn’s approvalnews2025-03-21T15:28:10+00:00March 21st, 2025|Endpoints News|
Elevation Oncology stops work on ADC, lays off workers; AstraZeneca’s CEPI fundingnews2025-03-20T15:10:58+00:00March 20th, 2025|Endpoints News|
Empress Therapeutics confirms layoffs; Nanobiotix amends J&J deal termsnews2025-03-18T15:01:13+00:00March 18th, 2025|Endpoints News|
Vertanical’s Phase 3 win for non-opioid painkiller; Apriori lays off 40% of staff news2025-03-17T14:58:51+00:00March 17th, 2025|Endpoints News|
Altimmune to put its incretin into addiction trials; Tarsus aims to raise $125Mnews2025-03-14T15:17:18+00:00March 14th, 2025|Endpoints News|
